Medication info
Bosomezol Tablet 40mg (Esomeprazole Magnesium Trihydrate)

Bosomezol Tablet 40mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›43.38mg / 1 tablet
Manufacturer / importer
Bugwang Pharmaceutical Co., Ltd.
Appearance
Pink, round, film-coated tablet
Packaging
28 tablets/PTP
Approval status
Active

MFDS item code 201506832 · Approved 2015.09.30 · Insurance code 642203980

Summary

Main use
Treatment of gastroesophageal reflux disease (erosive esophagitis and symptoms) and Helicobacter pylori-positive peptic ulcers; treatment to relieve NSAID-related gastrointestinal symptoms, etc.
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the drug for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg once daily may be taken as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 2) Concomitant antibiotic therapy for eradication of Helicobacter pylori Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring ongoing administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses exceeding 80 mg daily should be divided into 2 doses per day. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks after intravenous induction to prevent rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is required. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is required in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug must not exceed 20 mg. 6. Older adults No dose adjustment is required.
Children's dosage
Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the drug for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg once daily may be taken as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. Children under 12 years of age There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Bugwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastroesophageal reflux disease (erosive esophagitis and symptoms) and Helicobacter pylori-positive peptic ulcers; treatment to relieve NSAID-related gastrointestinal symptoms, etc.

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication helps in the treatment of gastroesophageal reflux disease, especially erosive reflux esophagitis, and prevents recurrence in patients with esophagitis. It also alleviates reflux symptoms in those without esophagitis. Additionally, it is used for the treatment of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection and is included in antibiotic combination therapy for prevention of recurrence. It is effective as short-term therapy for treating upper gastrointestinal symptoms associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). For patients who are on long-term NSAID therapy, it helps in treating gastric ulcers and preventing ulcers. It is also used for the treatment of Zollinger-Ellison syndrome and maintenance therapy to prevent rebleeding from gastric or duodenal ulcers after intravenous infusion. It is effectively used for various gastric diseases and related symptoms.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the drug for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg once daily may be taken as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. 2) Concomitant antibiotic therapy for eradication of Helicobacter pylori Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring ongoing administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses exceeding 80 mg daily should be divided into 2 doses per day. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks after intravenous induction to prevent rebleeding due to gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is required. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is required in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug must not exceed 20 mg. 6. Older adults No dose adjustment is required.

Children's dosage

Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the drug for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg once daily may be taken as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to administration of nonsteroidal anti-inflammatory drugs. Children under 12 years of age There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to individuals with allergies to this drug or its components, or to those with hypersensitivity to certain antibiotics. Additionally, women with a history of myocardial infarction or who are breastfeeding should not take this medication. Patients should be cautious as various adverse reactions can occur when taking this drug. For instance, there may be a decrease in blood cell count, allergic reactions, gastrointestinal disturbances, liver dysfunction, skin rashes, and others. Regular monitoring is necessary for those on long-term therapy, and immediate consultation with a doctor is required if symptoms change. This drug suppresses gastric acid secretion, which may increase the risk of bacterial infections in the gastrointestinal tract, so special caution should be taken, especially in hospitalized patients if diarrhea persists. Long-term use may increase the risk of fractures, hence patients at risk for osteoporosis require periodic monitoring. Furthermore, this drug may interact with other medications, so any other drugs being taken must be reported to healthcare providers. The safety of this medication during pregnancy has not been sufficiently established, so it should be used with caution, and it is advisable not to take it during breastfeeding. In the case of overdose, there is no specific antidote, and treatment should be symptomatic and supportive. Lastly, this medication should be kept out of reach of children, and transferring it to other containers should be avoided.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, hives, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, general edema, leg edema, malaise, pain, rigidity, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatic polymyalgia, anorexia, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, worsening of migraine, sleep disorder, tremors, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal pruritus, erythematous rash, papular rash, otitis media, abnormal olfaction, loss of taste, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly closed container. Also, it is recommended to store it at room temperature between 1°C and 30°C. This helps maintain the effectiveness of the medication for an extended period.

Appearance and packaging

Appearance

Pink, round, film-coated tablet

Package unit

28 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.